A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.
By D. Jayne, N. Rasmussen, K. Andrassy, P. Bacon, J. Tervaert, J. Dadonienė, A. Ekstrand, G. Gaskin, G. Gregorini, K. de Groot and 9 more. New England Journal of Medicine, 2003
1,363 citations recorded by the source corpus.
Subfields: Epidemiology, Pulmonary and Respiratory Medicine, Rheumatology
View Paper: https://www.semanticscholar.org/paper/d4fbfd42a290e96c1f13bbec91ed838e76dac303
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Pulmonary and Respiratory Medicine
In Rheumatology
Citations in the corpus
- Histopathologic classification of ANCA-associated glomerulonephritis. (2010, neutral): “Focal 8 (50) 7 ( 44) 0 (0) 1 ( 6) 16 (100) Crescentic 3 ( 6) 29 ( 53) 8 ( 15) 15 ( 27) 55 (100) Mixed 1 ( 6) 7 ( 44) 4 (25) 4 (25) 16 (100) Sclerotic 0 (0) 4 (31) 4 (31) 5 (39) 13 (100) SPECIAL ARTICLE www.”
- EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis (2016, background): “25 mg/kg per day by 12 weeks) and 93% were in remission by six months (76).”
- The Five-Factor Score Revisited: Assessment of Prognoses of Systemic Necrotizing Vasculitides Based on the French Vasculitis Study Group (FVSG) Cohort (2011, neutral): “Ophthalmologic manifestations 32 (9) 13 (6) 19 (8) 97 (31) 161 (15)”
- EULAR recommendations for the management of primary small and medium vessel vasculitis (2008, background): “It is common practice to commence prednisolone or prednisone at 1 mg/kg/day as in recent clinical trials.(31) 33 56 The initial high dose should be maintained for”
- KDIGO Clinical Practice Guideline for Glomerulonephritis (2012, methodology): “5 mg daily) for 412 months.(711) In other cohort studies, corticosteroids are tapered completely off by the end of 5 months if the patient is in remission.”